BOSTON, April 16, 2026 (GLOBE NEWSWIRE)-- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 ...
Spyre Therapeutics’ monoclonal antibody hit the key goal in a phase 2 study for ulcerative colitis (UC), which the company has touted as proof it can best Takeda’s Entyvio. The mid-stage trial ...
Have you ever watched a toddler try to put on their own shoes? It’s a masterclass in concentration. They’re balancing, pulling, and—hopefully—not throwing the shoe across the room in frustration. That ...
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming ...
Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage therapeutics company advancing novel neuropsychiatric medicines with a proven strategy and team, today announced positive topline ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Lynk Pharmaceuticals has reported another phase 3 win in China for its next-gen JAK inhibitor, this time hitting skin clearance goals among patients with eczema. The Hangzhou, China-based biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results